株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

掻痒:市場考察、疫学、市場予測

Pruritus - Market Insight, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 534824
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
掻痒:市場考察、疫学、市場予測 Pruritus - Market Insight, Epidemiology and Market Forecast - 2028
出版日: 2019年01月01日 ページ情報: 英文 100 Pages
概要

当レポートでは、世界の掻痒 - 特にアトピー性皮膚炎に伴うもの - の市場について分析し、疾患の概要や現在の治療手法/アルゴリズム、新たな治療薬の開発・上市の動き、主要製品の概要、世界全体および主要国 (米国・欧州諸国・日本) の市場動向 (今後11年間分)、主な市場促進・抑制要因、現在のアンメットニーズ、潜在的な市場機会などについて調査しております。

第1章 イントロダクション

第2章 掻痒:市場概略

  • 市場シェア構造 (最新値・予測値)

第3章 疾患の背景事情と概要:掻痒

  • 病因
  • リスク要因
  • 病態生理
  • 診断方法 (米国・英国・日本)

第4章 疫学と患者人口

  • 疾患の定義
  • 患者人口と予測パラメーター
  • 患者人口の計測方法
  • 主要7ヶ国 (7MM) のアトピー性皮膚炎の有病者数
  • 主要7ヶ国 (7MM) のアトピー性皮膚炎の有病者数:重症度別
  • 主要7ヶ国 (7MM) のアトピー性皮膚炎の有病者数:痒みの程度別
  • アトピー性皮膚炎の有病者数:痒みの程度別 (中程度の場合)
  • 未治療のアトピー性皮膚炎の有病者数:主要7ヶ国 (7MM) の場合
  • 未治療のアトピー性皮膚炎の有病者数:主要7ヶ国 (7MM) の場合、児童/成人別

第5章 治療手法

  • 治療アルゴリズム
  • 治療の目標
  • 第一選択療法
  • 第二選択療法

第6章 治療の失敗

第7章 クラス別の治療法

  • 局所治療
  • 全身治療
  • アトピー性皮膚炎向け認証済み治療薬

第8章 新規の治療薬

第9章 主要製品の相互比較

第10章 ネモリズマブ:Galderma Pharma

  • 製品概略
  • 研究開発 (R&D)
  • 製品開発の動き

第11章 トラロキヌマブ:LEO Pharma

第12章 トラジピタント:Vanda Pharmaceuticals

第13章 ZPL-389:Novartis

第14章 NST-141:日本新薬

第15章 セルロピタント:Menlo Therapeutics

第16章 DS107:DS Biopharma

第17章 アシマドリン:Tioga Pharmaceuticals

第18章 GSK2894512:GlaxoSmithKline

第19章 レブリキズマブ:Roche

第20章 DMT210:Dermata Therapeutics

第21章 SNA-120:Sienna Biopharmaceutical

第22章 RVT-501:Roivant Sciences

第23章 OPA-15406:大塚製薬

第24章 現状のアンメットニーズ

第25章 アトピー性皮膚炎による掻痒:市場分析

  • 市場の将来展望
  • 主要7ヶ国 (7MM) のアトピー性皮膚炎の市場規模
  • 主要7ヶ国 (7MM) のアトピー性皮膚炎による掻痒の市場規模

第26章 アトピー性皮膚炎による掻痒:米国市場の展望

  • 米国の市場規模

第27章 アトピー性皮膚炎による掻痒:欧州市場の展望

  • ドイツの市場規模
  • フランスの市場規模
  • イタリアの市場規模
  • スペインの市場規模
  • 英国の市場規模

第28章 アトピー性皮膚炎による掻痒:日本市場の展望

  • 日本の市場規模

第29章 市場促進要因

第30章 市場抑制要因

第31章 専門家の見解

第32章 現在の治療オプションに対する見解

第33章 新規の治療薬に関する見解

第34章 付録

第35章 分析手法

  • 利用した情報源

第36章 DelveInsightのサービス内容

第37章 免責事項

第38章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Pruritus in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Pruritus in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Pruritus in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Pruritus in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Pruritus in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Pruritus in United States (2016-2028)
  • Table 7: Treatable Cases of the Pruritus in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Pruritus in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Pruritus in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Pruritus in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Pruritus in Germany (2016-2028)
  • Table 12: Treatable Cases of the Pruritus in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Pruritus in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Pruritus in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Pruritus in France (2016-2028)
  • Table 16: Diagnosed Cases of the Pruritus in France (2016-2028)
  • Table 17: Treatable Cases of the Pruritus in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Pruritus in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Pruritus in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Pruritus in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Pruritus in Italy (2016-2028)
  • Table 22: Treatable Cases of the Pruritus in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Pruritus in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Pruritus in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Pruritus in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Pruritus in Spain (2016-2028)
  • Table 27: Treatable Cases of the Pruritus in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Pruritus in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Pruritus in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Pruritus in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Pruritus in UK (2016-2028)
  • Table 32: Treatable Cases of the Pruritus in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Pruritus in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Pruritus in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Pruritus in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Pruritus in Japan (2016-2028)
  • Table 37: Treatable Cases of the Pruritus in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Pruritus in USD MM (2016-2028)
  • Table 42:7MM- Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Pruritus in USD MM (2016-2028)
  • Table 45: United States-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Pruritus in USD MM (2016-2028)
  • Table 48: Germany-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Pruritus in USD MM (2016-2028)
  • Table 51: France-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Pruritus in USD MM (2016-2028)
  • Table 54: Italy-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Pruritus in USD MM (2016-2028)
  • Table 57: Spain-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Pruritus in USD MM (2016-2028)
  • Table 60:UK-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Pruritus in USD MM (2016-2028)
  • Table 63: Japan-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Pruritus by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Pruritus in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Pruritus in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Pruritus in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Pruritus in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Pruritus in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Pruritus in United States (2016-2028)
  • Figure 7: Treatable Cases of the Pruritus in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Pruritus in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Pruritus in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Pruritus in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Pruritus in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Pruritus in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Pruritus in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Pruritus in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Pruritus in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Pruritus in France (2016-2028)
  • Figure 17: Treatable Cases of the Pruritus in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Pruritus in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Pruritus in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Pruritus in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Pruritus in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Pruritus in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Pruritus in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Pruritus in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Pruritus in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Pruritus in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Pruritus in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Pruritus in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Pruritus in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Pruritus in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Pruritus in UK (2016-2028)
  • Figure 32: Treatable Cases of the Pruritus in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Pruritus in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Pruritus in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Pruritus in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Pruritus in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Pruritus in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Pruritus in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Pruritus in USD MM (2016-2028)
  • Figure 45: United States-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Pruritus in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Pruritus in USD MM (2016-2028)
  • Figure 51: France-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Pruritus in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Pruritus in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Pruritus in USD MM (2016-2028)
  • Figure 60:UK-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Pruritus in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Pruritus by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Pruritus by Therapies in USD MM (2016-2028)
目次
Product Code: DIMI0184

DelveInsight's "Pruritus - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Pruritus epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Pruritus Understanding and Treatment Algorithm

The market report provides the overview of the Pruritus by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Pruritus Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Pruritus in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Pruritus Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Pruritus Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Pruritus market.

Pruritus Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Pruritus Report Insights

  • Patient Population in Pruritus
  • Therapeutic Approaches in Pruritus
  • Pruritus Pipeline Analysis
  • Pruritus Market Size and Trends
  • Pruritus Market Opportunities
  • Impact of upcoming Therapies in Pruritus

Pruritus Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Pruritus Report Assessment

  • Current Treatment Practices in Pruritus
  • Unmet Needs in Pruritus
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Pruritus market
  • Organize sales and marketing efforts by identifying the best opportunities for Pruritus market
  • To understand the future market competition in the Pruritus market.

Table of Contents

1. Report Introduction

2. Pruritus Market Overview at a Glance

  • 2.1. Market Share Distribution of Pruritus in 2016
  • 2.2. Market Share Distribution of Pruritus in 2028

3. Disease Background and Overview: Pruritus

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Pruritus in 7MM
  • 4.3. Total Prevalent Patient Population of Pruritus in 7MM - By Countries

5. Epidemiology of Pruritus by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Pruritus
    • 5.1.3. Sub-Type Specific cases of the Pruritus *
    • 5.1.4. Sex- Specific Cases of the Pruritus *
    • 5.1.5. Diagnosed Cases of the Pruritus
    • 5.1.6. Treatable Cases of the Pruritus
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Pruritus
    • 5.4.3. Sub-Type Specific cases of the Pruritus *
    • 5.4.4. Sex- Specific Cases of the Pruritus *
    • 5.4.5. Diagnosed Cases of the Pruritus
    • 5.4.6. Treatable Cases of the Pruritus
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Pruritus
    • 5.5.3. Sub-Type Specific cases of the Pruritus *
    • 5.5.4. Sex- Specific Cases of the Pruritus *
    • 5.5.5. Diagnosed Cases of the Pruritus
    • 5.5.6. Treatable Cases of the Pruritus
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Pruritus
    • 5.6.3. Sub-Type Specific cases of the Pruritus *
    • 5.6.4. Sex- Specific Cases of the Pruritus *
    • 5.6.5. Diagnosed Cases of the Pruritus
    • 5.6.6. Treatable Cases of the Pruritus
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Pruritus
    • 5.7.3. Sub-Type Specific cases of the Pruritus *
    • 5.7.4. Sex- Specific Cases of the Pruritus *
    • 5.7.5. Diagnosed Cases of the Pruritus
    • 5.7.6. Treatable Cases of the Pruritus
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Pruritus
    • 5.8.3. Sub-Type Specific cases of the Pruritus *
    • 5.8.4. Sex- Specific Cases of the Pruritus *
    • 5.8.5. Diagnosed Cases of the Pruritus
    • 5.8.6. Treatable Cases of the Pruritus
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Pruritus
    • 5.9.3. Sub-Type Specific cases of the Pruritus *
    • 5.9.4. Sex- Specific Cases of the Pruritus *
    • 5.9.5. Diagnosed Cases of the Pruritus
    • 5.9.6. Treatable Cases of the Pruritus

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Pruritus

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Pruritus

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Pruritus : 7MM Market Analysis

  • 12.1. 7MM Market Size of Pruritus
  • 12.2. 7MM Percentage Share of drugs marketed for Pruritus
  • 12.3. 7MM Market Sales of Pruritus by Products

13. Pruritus : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Pruritus in United States
    • 13.1.2. Percentage Share of drugs marketed for Pruritus in United States
    • 13.1.3. Market Sales of Pruritus by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Pruritus in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Pruritus in Germany
      • 13.2.1.3. Market Sales of Pruritus by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Pruritus in France
      • 13.2.2.2. Percentage Share of drugs marketed for Pruritus in France
      • 13.2.2.3. Market Sales of Pruritus by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Pruritus in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Pruritus in Italy
      • 13.2.3.3. Market Sales of Pruritus by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Pruritus in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Pruritus in Spain
      • 13.2.4.3. Market Sales of Pruritus by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Pruritus in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Pruritus in United Kingdom
      • 13.2.5.3. Market Sales of Pruritus by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Pruritus in Japan
    • 13.3.2. Percentage Share of drugs marketed for Pruritus in Japan
    • 13.3.3. Market Sales of Pruritus by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

Back to Top